According to the company, the technology is a highly sensitive and accurate method of detecting and quantifying cellular responses, allowing greater specificity, quantification, and amplification of clinical and commercial opportunities.
The technology underpins the AditxtScore platform, allowing for a standardization of cellular assays.
These assays can then be used as a development platform for clinical utility. Applications of the technology can be used to profile individuals to select appropriate therapies and assess immune status before, during, and after therapeutic intervention.
Aditxt develops technologies focused on improving immune system health through immune monitoring and reprogramming.
Aditxt's immune monitoring technology is designed to provide a personalized, comprehensive system immune system profile.
Aditxt's immune reprogramming technology, currently preclinical, is designed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases, and allergies.
AditxtScore for COVID-19 is Aditxt's proprietary immune profile technology to equip people with information about their level of protection.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Innovent Biologics announces CFO transition
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial